#United States #FDA Approval #Minneapolis #Neurapheresis #Pharaoh Neuro

Pharaoh Neuro's Neurapheresis™ CSF Management System Receives FDA's Breakthrough Device Designation

In a landmark development for neurocritical care, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Pharaoh Neuro, Inc.’s Neurapheresis™ Cerebrospinal Fluid (CSF) Management System. This advanced device aims to improve treatment outcomes for patients following an aneurysmal subarachnoid hemorrhage (aSAH) by enhancing the removal of blood and its breakdown products from cerebrospinal fluid.

Pharaoh Neuro, a Minneapolis-based company focused on innovative medical device solutions, announced this significant recognition following its ongoing commitment to addressing critical needs in the field of neurointervention.

A Highlight on aSAH

Each year, approximately 30,000 individuals in the United States suffer from aneurysmal subarachnoid hemorrhages. This serious type of hemorrhagic stroke primarily affects younger adults and can leave lasting consequences for survivors, including challenges in returning to functional independence and employment. Given the urgency for effective treatment options, the Neurapheresis System is positioned as a promising alternative to existing passive drainage solutions.

Currently, standard methods for managing CSF pressure post-aSAH involve passive drainage techniques that lack the ability to actively filter blood products from the CSF. Unlike these methods, the groundbreaking Neurapheresis System introduces a closed-loop automated platform designed to aspirate, filter, and return CSF without the need for replacement fluids. This not only optimizes the blood removal process but also has potential implications for improving patient outcomes in a critically challenging area of care.

As highlighted by Pharaoh Neuro’s CEO, Amaza Reitmeier, this designation affirms their belief in the transformative capabilities of Neurapheresis over currently available alternatives. Reitmeier expressed eagerness to collaborate closely with the FDA to expedite the technology’s availability to patients.

Clinical Validation and Future Prospects

To assess the safety and effectiveness of the Neurapheresis System, Pharaoh Neuro has initiated the PILLAR-XT4 clinical trial, published in the journal Neurocritical Care. The trial aimed at proving the efficacy of the new system was led by Dr. Spiros L. Blackburn, a Professor of Neurosurgery. He confirmed that the study showcased significant advancements in actively filtering blood and its breakdown products from CSF. Such strides are crucial for patients with few viable treatment alternatives.

Dr. Nandan Lad, the Chief Medical Officer of Pharaoh Neuro and the inventor associated with the Neurapheresis System, reiterated the importance of fulfilling a critical clinical requirement through an evidence-based approach, which was endorsed by the FDA’s Breakthrough designation. This strategic status facilitates a more favorable interaction with the FDA, potentially expediting the marketing authorization process.

The Neurapheresis System showcases innovative breakthroughs essential in managing CSF during and post-critical neurointervention situations. With its acknowledgment by the FDA and active engagement in the Total Product Lifecycle Advisory Program (TAP) Pilot, Pharaoh Neuro is mapping out a proactive pathway toward bringing an active approach in CSF management to patients in dire need.

As Pharaoh Neuro propels forward, both the medical community and stakeholders within neurocritical care eagerly await the outcomes of their efforts, which signify a glimmer of hope for those affected by aSAH. By continuing their commitment to innovation, Pharaoh Neuro stands at the forefront of a promising shift in treatment paradigms for patients facing severe neurological challenges.

For more updates on this development, stay tuned to Pharaoh Neuro's official communications or explore their website at pharaohneuro.com.

About Breakthrough Device Designation

The FDA's Breakthrough Devices Program is a voluntary scheme aimed at streamlining the development and review processes for medical devices that offer significant improvements in the treatment of life-threatening or debilitating conditions. This designation does not constitute an approval for commercialization but rather accelerates the regulatory path for devices that meet stringent criteria.

As the Neurapheresis System continues its regulatory journey, the medical landscape anticipates the bright potential it holds for revolutionizing care in neurocritical settings.